尼莫地平与升压药对自发性蛛网膜下腔出血后迟发性脑缺血患者结局的影响
该2中心回顾性数据库分析纳入2008至2016年治疗的732例自发性蛛网膜下腔出血患者,评估尼莫地平与升压药对结局的影响。397例随访患者中260例(65.5%)获得良好结局(mRS 0-3分)。多因素分析显示尼莫地平、年龄和CRP水平是良好结局的独立预测因素;作者认为更高剂量的升压药可安全地实现最大剂量尼莫地平给药。
要点
- 397例随访患者中260例(65.5%)获得良好结局(mRS 0-3分)。
- 尼莫地平(p=0.049)、年龄(p=0.049)和CRP水平(p=0.002)是良好结局的独立预测因素。
- WFNS IV或V级患者中,升压药剂量(p=0.030)和尼莫地平剂量(p=0.049)是独立预测因素。
核心结论
- 作者认为,更高剂量的升压药可安全地实现最大剂量尼莫地平给药。
- 严重SAH(WFNS IV或V级)患者的总升压药剂量截断值超过轻症患者的3倍以上,而尼莫地平截断值在轻症与重症患者中保持相似。
- 作者认为,尽管SAH患者需要更高剂量的升压药,但能够达到最大尼莫地平剂量是令人鼓舞的。
研究设计与样本
- 2中心回顾性临床数据库分析,纳入2008年至2016年治疗的732例自发性蛛网膜下腔出血患者。
- 评估年龄、性别、WFNS分级、BMI、Fisher分级、动脉高血压史、吸烟史、动脉瘤位置、CRP水平及治疗期间升压药和尼莫地平详细剂量等数据。
- 采用治疗后6个月改良Rankin量表(mRS)分析临床结局,并进行单因素和多因素回归分析。
- 另评估平均动脉压(MAP)、年龄、尼莫地平和升压药剂量截断值与结局的关系,显著性水平设定为≤0.05。
主要发现
- 397例患者完成随访,其中260例(65.5%)获得良好结局(定义为mRS评分0-3分)。
- 单因素和多因素分析证实尼莫地平(p=0.049)、年龄(p=0.049)和CRP水平(p=0.002)是良好结局的独立预测因素。
- 单因素分析中WFNS分级、Fisher评分、高血压、初始脑积水和总升压药剂量对结局有显著影响;患者性别、吸烟状态、BMI和MAP与结局无显著关联。
- 对较轻初始SAH(WFNS I-III级)患者的亚组分析显示,初始脑积水(p=0.003)和CRP水平(p=0.001)对进一步结局有显著影响。
- 仅评估WFNS IV或V级患者时,年龄、CRP水平(p=0.011)、升压药剂量(p=0.030)和尼莫地平剂量(p=0.049)是患者结局的独立预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Delayed cerebral ischemia (DCI) is a major factor contributing to the inferior outcome of patients with spontaneous subarachnoid hemorrhage (SAH). Nimodipine and induced hypertension using vasopressors are an integral part of standard therapy. Consequences of the opposite effect of nimodipine and vasopressors on blood pressure on patient outcome remain unclear. The authors report the detailed general characteristics and influence of nimodipine and vasopressors on outcome in patients with SAH. METHODS: The authors performed a 2-center, retrospective, clinical database analysis of 732 SAH patients treated between 2008 and 2016. Demographic and clinical data such as age, sex, World Federation of Neurosurgical Societies (WFNS) grade, BMI, Fisher grade, history of arterial hypertension and smoking, aneurysm location, C-reactive protein (CRP) level, and detailed dosage of vasopressors and nimodipine during the treatment period were evaluated. Clinical outcome was analyzed using the modified Rankin Scale (mRS) 6 months after treatment. Univariate and multivariate regression analyses were performed. Additionally, mean arterial pressure (MAP), age, nimodipine, and vasopressor dose cutoff were evaluated with regard to outcome. The level of significance was set at ≤ 0.05. RESULTS: Follow-up was assessed for 397 patients, 260 (65.5%) of whom achieved a good outcome (defined as an mRS score of 0-3). Univariate and multivariate analyses confirmed that nimodipine (p = 0.049), age (p = 0.049), and CRP level (p = 0.002) are independent predictors of good outcome. WFNS grade, Fisher score, hypertension, initial hydrocephalus, and total vasopressor dose showed significant influence on outcome in univariate analysis, and patient sex, smoking status, BMI, and MAP showed no significant association with outcome. A subgroup analysis of patients with milder initial SAH (WFNS grades I-III) revealed that initial hydrocephalus (p = 0.003) and CRP levels (p = 0.001) had significant influence on further outcome. When evaluating only patients with WFNS grade IV or V, age, CRP level (p = 0.011), vasopressor dose (p = 0.030), and nimodipine dose (p = 0.049) were independent predictors of patient outcome. Patients with an MAP < 93 mm Hg, a nimodipine cutoff dose of 241.8 mg, and cutoff total vasopressor dose of 523 mg had better outcomes. CONCLUSIONS: According to the authors' results, higher doses of vasopressors can safely provide a situation in which the maximum dose of nimodipine could be administered. Cutoff values of the total vasopressor dose were more than 3 times higher in patients with severe SAH (WFNS grade IV or V), while the nimodipine cutoff remained similar in patients with mild and severe SAH. Hence, it seems encouraging that a maximum nimodipine dosage can be achieved despite the need for a higher vasopressor dose in patients with SAH.
引用
- Paľa A, Schick J, Klein M, et al. The influence of nimodipine and vasopressors on outcome in patients with delayed cerebral ischemia after spontaneous subarachnoid hemorrhage. J Neurosurg. 2019. PMID: 30849754. doi:10.3171/2018.11.JNS182891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。